Scientists successfully control when genetically engineered non-toxic bacteria, after intravenously injected, invades cancer cells and delivers cancer-fighting drugs directly into tumors in mouse models, sparing healthy tissue, and delivering more therapy as the bacteria grow in the tumors.
Read Full Article
#CancerResearch #GeneEngineering #TargetedTherapy #PrecisionMedicine #BiomedicalInnovation
Read Full Article
#CancerResearch #GeneEngineering #TargetedTherapy #PrecisionMedicine #BiomedicalInnovation
University of Massachusetts
Research Using Non-Toxic Bacteria to Fight High-Mortality Cancers Prepares for Clinical Trials
The latest breakthrough from a team of UMass Amherst and Ernest Pharmaceutical researchers uses aspirin in its targeted drug delivery therapy.
👏4🤡1
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer: Clinical trial finds 60.9% overall response rate (ORR) with combination of encorafenib, cetuximab and mFOLFOX6 compared to 40% with standard-of-care (SOC) treatment.
Read Full Article
#BRAFmutated #ColorectalCancer #TargetedTherapy #ClinicalTrial #CancerResearch
Read Full Article
#BRAFmutated #ColorectalCancer #TargetedTherapy #ClinicalTrial #CancerResearch
EurekAlert!
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER…
👏1
Scientists Discover Plant Compound That Forces Aggressive Breast Cancer Cells Into Self-Destruction. Interfering with a key metabolic enzyme, the compound demonstrated broad antitumor effects across advanced experimental models.
Read Full Article
#CancerResearch #PlantCompound #TargetedTherapy #AntitumorEffects #ScienceNews
Read Full Article
#CancerResearch #PlantCompound #TargetedTherapy #AntitumorEffects #ScienceNews
Researchers at the University of Colorado Anschutz found that a class of targeted cancer drugs known as tyrosine kinase inhibitors can change how taste buds are maintained, altering flavor perception overall.
Read Full Article
#CancerResearch #TargetedTherapy #TasteChanges
Read Full Article
#CancerResearch #TargetedTherapy #TasteChanges
CU Anschutz Medical Campus
Some Cancer Drugs Disrupt Taste by Changing the Cells Inside Taste Buds, Study Shows
Some Cancer Drugs Disrupt Taste by Changing the Cells Inside Taste Buds, Study Shows
Phase III HUMAN study shows that new pill for patients with advanced pancreatic cancer live significantly longer than standard chemotherapy
Read Full Article
#PancreaticCancer #PhaseIII #TargetedTherapy
Read Full Article
#PancreaticCancer #PhaseIII #TargetedTherapy
The New England Journal of Medicine
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | NEJM
Current therapies offer limited benefit for patients with previously treated metastatic
pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is
the key driver of PDAC, w...
pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is
the key driver of PDAC, w...
Science News
Study Finds Chemotherapy-Free Treatment Shows Promise for Some Patients With Metastatic Breast Cancer. In the trial, 97% of patients experienced clinical benefit during the first 6 months of treatment. After a median follow-up of approximately 39 months, nearly…
✨ Chemo-Free Breast Cancer Treatment Shows Promise: A Phase 1/2 clinical trial found a combination of four targeted therapies effective for HR-positive, HER2-positive metastatic breast cancer patients, potentially offering an alternative to chemotherapy.
📈 High Patient Benefit: In the ASPIRE trial, 97% of patients experienced clinical benefit within six months, with a median progression-free survival of nearly 25 months. Nearly 93% were still alive after about 39 months of follow-up.
💊 Manageable Side Effects: The treatment's side effects were generally expected, including low white blood cell counts and diarrhea. Only one patient stopped treatment due to side effects, with no treatment-related deaths reported.
#BreastCancer #TargetedTherapy #Oncology
📈 High Patient Benefit: In the ASPIRE trial, 97% of patients experienced clinical benefit within six months, with a median progression-free survival of nearly 25 months. Nearly 93% were still alive after about 39 months of follow-up.
💊 Manageable Side Effects: The treatment's side effects were generally expected, including low white blood cell counts and diarrhea. Only one patient stopped treatment due to side effects, with no treatment-related deaths reported.
#BreastCancer #TargetedTherapy #Oncology